You are here: Industry Insights > GVHD

News List

Combining pacritinib with sirolimus-based GvHD prophylaxis may improve efficacy europeanpharmaceuticalreview
March 25, 2021
Phase I results suggest adding pacritinib to sirolimus and low-dose tacrolimus could be beneficial in preventing graft-versus-host disease (GvHD).
Markets for GvHD in five APAC markets to grow at 8.2 per cent CAGR in 10 years: GlobalData expresspharma
August 28, 2020
The impact of approved therapies replacing generic off-label treatments will be the main driver of growth in the 5GM GvHD market.
Novartis' Jakavi bests current therapy for GvHD pharmatimes
April 26, 2020
Results of the Phase III REACH2 study show that Novartis' Jakavi (ruxolitinib) improves outcomes across a range of efficacy measures in patients with steroid-refractory acute graft-versus-host disease (GvHD) compared to best available therapy (BAT).
Itacitinib Study for Treatment-Naïve Acute Graft-Versus-Host Disease Does Not Meet Primary Endpoint americanpharmaceuticalreview
January 06, 2020
Incyte announced the pivotal Phase 3 GRAVITAS-301 study evaluating itacitinib in combination with corticosteroids in patients with treatment-naïve acute graft-versus-host disease (GVHD) did not meet the primary endpoint of improving overall response rate
BMS’ Orencia gets breakthrough status in US to prevent GvHD pharmaceutical-technology
December 09, 2019
Bristol-Myers Squibb (BMS) has received breakthrough device designation for its Orencia (abatacept) drug to prevent moderate to severe acute graft-versus-host disease (GvHD).
Cellect Biotechnology, Washington University Finalize Accelerated Clinical Trial Agreement americanpharmaceuticalreview
July 09, 2019
As the two organizations move closer to the commencement of the clinical trial to determine the safety and tolerability of the Apograft technology for bone marrow transplantations ...
Abatacept improves survival in patients with acute GvHD europeanpharmaceuticalreview
December 12, 2017
A drug used to treat rheumatoid arthritis improves survival after hematopoietic stem cell transplant…
FDA green lights first treatment for chronic GvHD pharmatimes
August 04, 2017
The US Food and Drug Administration has expanded the scope of Johnson & Johnson/AbbVie’s Imbruvica to include the treatment of adult patients with chronic graft versus host disease (cGVHD) after failure of one or more treatments...